Lifeline Scientific, the medical technology company focused on the development and
commercialization of advanced organ preservation and transport systems designed to
address the global challenge of human donor organ shortages, issues the following
trading update for the six months ended 30 June 2010.
Following a landmark 2009, during which Lifeline recorded its first full-year operating
profit, the Company has experienced steady growth during 2010. Revenue for the first
half is expected to be at least in line with current market expectations while operating
profit is expected to be significantly ahead of last year’s maiden interim operating profit.
The Company expects to announce interim results in September.
Lifeline Scientific, Inc. + 1 847 294 0300
David Kravitz, CEO
Seymour Pierce (Nomad) +44 (0)20 7107 8000
Financial Dynamics +44 (0)20 7831 3113
Ben Brewerton / John Dineen
About the LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in mind, the Company’s lead
product, LifePort Kidney Transporter is designed to provide improved kidney
preservation, evaluation and transport prior to transplantation. LifePort provides a sealed,
sterile, protected environment where a physiologic solution is gently pumped through the
kidney at cold temperatures to minimize damage while the organ is being preserved
outside the body. LifePort is lightweight and portable, allowing organs to be perfused
from the time of recovery until transplant. It is designed to travel unaccompanied by land
or air, safely transporting the kidneys across town or between countries. While the
kidney is being perfused, the LifePort records data on temperature, flow rate vascular
resistance and pressure every 10 seconds providing surgeons with additional data prior to
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based medical technology company with European
headquarters located in Brussels. Serving leading transplant programs in 15 countries, it
is the largest company in the world dedicated exclusively to addressing unmet medical
needs in pre-transplant organ preservation, transport, evaluation and therapy. Its primary
commercial focus is the global launch of its FDA cleared, CE marked, clinically validated
and revenue generating LifePort Kidney Transporter. LifePort based product line
extensions for preservation of the liver, pancreas and other organs are in development.